Amplifying the Voice of Myositis Patients at FDA hosted by TMA and TMA Women With IBM Affinity Group

Amplifying the Voice of Myositis Patients at FDA: Applying Patient Advocacy to Advance Rare Disease Research at Government Agencies
As patients living with forms of myositis, how can we make our voices heard to advance research and find a cure? TMA and our TMA Women with IBM Affinity Group are excited to host Julia (Julie) C. Tierney, JD, Deputy Center Director for Strategy, Policy, and Legislation at the Center for Biologics Evaluation and Research (CBER) with the U.S. Food & Drug Administration (FDA). Ms. Tierney will join us to discuss how patient advocacy can help advance myositis research within government agencies.
A senior leader within FDA who served most recently as FDA Chief of Staff, Julie transitioned to her new role at CBER in January 2024. She joined a leadership team focused on addressing rapid scientific developments and taking on the challenges associated with regulating cell and gene therapies and other highly innovative products. CBER is the center within FDA that regulates biological products for human use, including immune globulin, vaccines, blood products, gene therapies, and monoclonal antibody treatments.
This presentation was recorded on May 9, 2024.